Komori
Presentation materials on financial results6568KNC Laboratories Co.,Ltd.Information and Communications, Services and Others

Supplementary Financial Results Information for the Fiscal Year Ending March 2026

For the fiscal year ended March 2026, revenue and profit both exceeded the previous outlook, driven by development projects and growing demand in functional materials, pharmaceuticals and biotechnology. For the fiscal year ending March 2027, the company did not issue full-year forecasts due to procurement and raw-material price risks arising from the Strait of Hormuz situation, and disclosed only a first-quarter forecast.

Worth reading
68In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
914
¥ millions (year-on-year change in revenue for the fiscal year ended March 2026)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Presentation materials on financial resultsFiscal year ending March 202612 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥9,093 million+11.2%
Operating profit¥1,024 million+32.7%
Ordinary income¥1,028 million+10.7%
Net income¥766 million+3.9%
Results for the three months of the current quarter
Fourth quarter of the fiscal year ended March 2026
Net Sales
¥3,499 million
Operating profit
¥870 million
Ordinary income
¥863 million
Net income
¥660 million
Adjusted EBITDA
¥1,197 million
Adjusted EBITDA margin
34.2 %
Full-year earnings forecast
Previous outlook published for the fiscal year ended March 2026
Net Sales
¥8,800 million
Operating profit
¥850 million
Ordinary income
¥850 million
Net income
¥600 million
Adjusted EBITDA
¥1,868 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Exceeded plan
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Impact of higher revenue5.4 Hundred millions of yen
  • Product mix variance0.2 Hundred millions of yen
  • Non-operating Income0.2 Hundred millions of yen
  • R&D expenses and AMED-related R&D expenses-0.2 Hundred millions of yen
  • Grant-1.5 Hundred millions of yen
  • Depreciation-1.5 Hundred millions of yen
  • Personnel expenses-0.5 Hundred millions of yen
  • Preparation costs for new FP-4 building-0.8 Hundred millions of yen
  • Other fixed costs-1.6 Hundred millions of yen
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
  • Dependence on the Strait of Hormuz (chemicals derived from crude oil, naphtha, etc.)80 %
  • Dependence on direct imports60 %
  • Sourced outside the Strait of Hormuz20 %
New initiatives
  • Completion of construction of the FP-4 building and planned start of operations from the fiscal year ending March 2027
  • Increase in sales staff and expansion of new orders
  • Stronger collaboration with academia and drug-discovery startups
  • LP investment in the DCIP Fund
  • Joint research with 光オンデマンドケミカル
  • Investment in イムノロック社
Key KPIsA metric the company considers important as a management benchmark.
  • Adjusted EBITDA¥1,951 million+10.8%
  • Adjusted EBITDA margin21.5 %
    yoy_changeFlat
  • New orders102 Hundred millions of yen
  • Productivity4 % vs. fiscal year ended March 2025
  • ROE5.6 %
Segment results
  • Functional Materials
    Net Sales¥3,056 million
  • Pharmaceuticals
    Net Sales¥3,927 million
  • Bio
    Net Sales¥2,109 million
Medium-term management plan targets
  • Revenue120 Hundred millions of yen
    Target fiscal yearFiscal year ending March 2028
  • Functional materials revenue40 Hundred millions of yen
    Target fiscal yearFiscal year ending March 2028
  • Pharmaceuticals revenue50 Hundred millions of yen
    Target fiscal yearFiscal year ending March 2028
  • Biotechnology revenue30 Hundred millions of yen
    Target fiscal yearFiscal year ending March 2028
  • Adjusted EBITDA margin30 %
    Target fiscal yearFiscal year ending March 2028
  • Net profit margin14 %
    Target fiscal yearFiscal year ending March 2028
  • ROE10 %
    Target fiscal yearFiscal year ending March 2028
Financial targets
ROE
Actual results5.5 %
Target10 %
Target fiscal yearFiscal year ending March 2028
Orders received and order backlog
New orders
¥28 hundred million fourth quarter of the fiscal year ended March 2026
Order backlog
¥26.7 hundred million fourth quarter of the fiscal year ended March 2026
Order backlog lead time
11.7 Months fourth quarter of the fiscal year ended March 2026
Number of employees
Change during the period21 People
Capital expenditures
¥2,640 million
Annual Dividend
Fiscal year ending March 2026
Annual¥33 per share
Interim¥16 per share
End of period¥17 per share
Fiscal year ending March 2027
Interim¥16 per share
End of periodUndecided
Contents of this document
ItemDetails
Document typePresentation materials on financial results
Fiscal Period CoveredFiscal year ending March 2026
Net Sales¥9,093 million (YoY +11.2%)
Operating profit¥1,024 million (YoY +32.7%)
Ordinary income¥1,028 million (YoY +10.7%)
Net income¥766 million (YoY +3.9%)
Results for the three months of the current quarterSubject Fourth quarter of the fiscal year ended March 2026 / Net Sales ¥3,499 million / Operating profit ¥870 million / Ordinary income ¥863 million / Net income ¥660 million / Adjusted EBITDA ¥1,197 million / Adjusted EBITDA margin 34.2 %
Full-year earnings forecastFiscal year ending March 2027 Not disclosed / Previous outlook published for the fiscal year ended March 2026 Net Sales ¥8,800 million / Operating profit ¥850 million / Ordinary income ¥850 million / Net income ¥600 million / Adjusted EBITDA ¥1,868 million
Self-assessment against the planExceeded plan
Segment resultsSegment Functional Materials / Net Sales ¥3,056 million / yoy_pct 1.8, Segment Pharmaceuticals / Net Sales ¥3,927 million / yoy_pct 11.9, Segment Bio / Net Sales ¥2,109 million / yoy_pct 26.5
Breakdown of Factors Affecting the ChangeFactors Impact of higher revenue / Amount 5.4 Hundred millions of yen, Factors Product mix variance / Amount 0.2 Hundred millions of yen, Factors Non-operating Income / Amount 0.2 Hundred millions of yen, Factors R&D expenses and AMED-related R&D expenses / Amount -0.2 Hundred millions of yen, Factors Grant / Amount -1.5 Hundred millions of yen, Factors Depreciation / Amount -1.5 Hundred millions of yen, Factors Personnel expenses / Amount -0.5 Hundred millions of yen, Factors Preparation costs for new FP-4 building / Amount -0.8 Hundred millions of yen, Factors Other fixed costs / Amount -1.6 Hundred millions of yen
Key KPIs¥1,951 million (YoY +10.8%), 21.5 %, 102 Hundred millions of yen, 4 % (vs. fiscal year ended March 2025), 5.6 %
Number of employeesChange during the period 21 People
Assumptions Underlying the Business OutlookDependence on the Strait of Hormuz (chemicals derived from crude oil, naphtha, etc.) 80 %, Dependence on direct imports 60 %, Sourced outside the Strait of Hormuz 20 %
Medium-term management plan targetsRevenue 120 Hundred millions of yen, Functional materials revenue 40 Hundred millions of yen, Pharmaceuticals revenue 50 Hundred millions of yen, Biotechnology revenue 30 Hundred millions of yen, Adjusted EBITDA margin 30 %, Net profit margin 14 %, ROE 10 %
Financial targetsROE Actual results 5.5 % / Target 10 % / Target fiscal year Fiscal year ending March 2028
Annual DividendFiscal year ending March 2026 Annual ¥33 per share / Interim ¥16 per share / End of period ¥17 per share / Fiscal year ending March 2027 Interim ¥16 per share / End of period Undecided
Capital expenditures¥2,640 million
Orders received and order backlogNew orders ¥28 hundred million (fourth quarter of the fiscal year ended March 2026) / Order backlog ¥26.7 hundred million (fourth quarter of the fiscal year ended March 2026) / Order backlog lead time 11.7 Months (fourth quarter of the fiscal year ended March 2026)
New initiativesCompletion of construction of the FP-4 building and planned start of operations from the fiscal year ending March 2027, Increase in sales staff and expansion of new orders, Stronger collaboration with academia and drug-discovery startups, LP investment in the DCIP Fund, Joint research with 光オンデマンドケミカル, Investment in イムノロック社
Items this document does not state (11)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesProgress against full-year forecastUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookPayout ratioAcquisition of treasury sharesMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The main drivers of higher revenue and profit in the fiscal year ended March 2026 were development-stage progress in the pharmaceutical and biotechnology fields exceeding expectations, increased demand for pharmaceutical, medical and semiconductor-related applications in functional materials, and contributions from the start-up of Building D and multiple development projects in biotechnology. Although costs such as personnel expenses increased, the impact was offset by higher revenue. The reason for not disclosing a full-year forecast for the fiscal year ending March 2027 is that the Strait of Hormuz situation has increased the risk of raw-material shortages and price spikes, making it difficult to reasonably calculate full-year results.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Financial Results Information for the Fiscal Year Ending March 2026 | KNC Laboratories Co.,Ltd. (6568) timely disclosure | Komori